



Kilitch Drugs (India) Ltd.

February 5, 2019

To,
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To,
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Dear Sir,

Sub: Intimation of Board Meeting

Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, We wish to inform you that a meeting of the Board of Directors of Kilitch Drugs (India) Limited ("the company") will be held on Tuesday, the 12th day of February, 2019, at 11.00 a.m. at its corporate office **at 37, Ujagar Industrial Estate, W.T. Patil Marg, Deonar, Mumbai- 400 088, Maharashtra, India, inter alia,**

1. To consider and approve the un-audited financial results of the company for the quarter ended December 31, 2018.
2. To consider the resignation of Mr. Shailesh Mirgal as a Chief Financial Officer of the Company.
3. To consider the appointment of CA Sujit Kumar Dash as a Chief Financial Officer of the Company.
4. To consider the appointment of M/s. Deep Shukla & Associates, Company Secretaries to conduct Secretarial Audit of the Company for financial year ended 31st March, 2019.
5. Any other matter with the permission of the chair.

Further pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company will be closed from February 5, 2018 to February 14, 2019 for the purpose of declaration of un-audited financial results of the Company for the the quarter ended December 31, 2018.

The above intimation is given to you pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours Faithfully,
For **Kilitch Drugs (India) Limited**


Mukund Mehta
Managing Director
(DIN:00147876)

